article thumbnail

Will Modernization of Cosmetic Regulation Finally Happen?

FDA Law Blog

While FDASLA focuses on user fees and includes several other provisions regarding drugs and devices, it also includes provisions related to cosmetics. a requirement for FDA to issue regulations to establish standardized testing methods for detecting and identifying asbestos in talc-containing products.

article thumbnail

Opinion: Congress needs to update FDA’s ability to regulate diagnostic tests, cosmetics

STAT News

Congress is considering two measures that modernize tools the Food and Drug Administration uses to oversee two areas of its vast portfolio: diagnostic tests and cosmetics. While the stakes are different for each of these industries, the basic premise driving these measures is the same. Read the rest…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DCGI issues show cause notice to e-pharmacies for stocking & selling drugs in contravention to D&C Act

AuroBlog - Aurous Healthcare Clinical Trials blog

The Drug Controller General of India (DCGI) has issued a show cause notice to online pharmacies including Tata 1mg for allegedly stocking and selling drugs in contravention of the provisions of the Drugs and Cosmetics Act, 1940 and Rules, once again bringing back the long pending issue of lack of regulations on e-pharmacies under the […]

Pharmacy 132
article thumbnail

TN DCA issues circular asking pharmacists in medical shops to wear white coat and badges

AuroBlog - Aurous Healthcare Clinical Trials blog

Although provisions of the Pharmacy Practice Regulations (PPR) 2015 are not there in the Drugs and Cosmetics (D&C) Act 1940 but are framed under the Pharmacy Act 1948, the steps now being taken by the drugs control administration (DCA) in Tamil Nadu in a motive to strengthen the dispensing activities in pharmacies are completely agreeing […] (..)

Cosmetics 149
article thumbnail

D&C Rules need revamp as there is no clause of compensation for ADRs: regulatory experts

AuroBlog - Aurous Healthcare Clinical Trials blog

Taking into account the four main components of regulator, industry, trade and patient/consumer in a medicine value supply chain, the Drugs and Cosmetics (D&C) Rules, 1945 and D&C Act, 1940 needs an urgent revamp as there is no clause of compensation for ADRs in patients, according to drug regulatory experts.

Cosmetics 147
article thumbnail

STAT+: Biden makes drug pricing a central part of his deficit reduction plans

STAT News

WASHINGTON — President Biden made lowering drug prices a key part of his budget with proposals to expand Medicare drug price negotiation, squeeze more rebates out of drug companies, and lower the cost of insulin for everyone with insurance. The request made Thursday also details a $7.2

article thumbnail

CBD Research: A Dive into the Regulations of Cannabis Research

Advarra

However, it’s not legal federally and is considered a Schedule I drug by the U.S. Drug Enforcement Administration (DEA), meaning it has no accepted medical use and a high potential for abuse. Even though CBD doesn’t meet criteria for IND exemption or the FDA’s OTC drug review, it still can be studied in humans.